CLINICAL OUTCOMES AND SURVIVAL RATES OVER THE 15-YEAR PERIOD IN PEDIATRIC PATIENTS WITH PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR OF BONE AND SOFT TISSUES IN REPUBLIC OF BELARUS
Abstract
Peripheral primitive neuroectodermal tumor (pPNET) can occur in any bone or soft tissue and is about a quarter of all pediatric patients with Ewing’s sarcoma family of tumors. The aim of this study was to investigate whether patient characteristics differ between the cases with favorable and unfavorable outcomes. Thus, 53 pediatric patients with pPNET from the Republic of Belarus reported to the sub-cancer registry database from 1999 to 2014 were evaluated. The survival rate was estimated by means of the Kaplan-Meier method and was compared using log-rank tests and Cox proportional hazard models. Overall survival (OS) was superior for localized pPNET compared with metastatic forms (70.3 % vs 20.0 %;
P = 0.0016). Fifteen-year OS for the entire cohort of patients was 60.2 %. Known clinical prognostic factors (age, sex, tumors volume, response to treatment and other) did not differ between patients with favorable and unfavorable outcomes.
Treatment results for pediatric patients with pPNET from the Republic of Belarus comply with the generally accepted standards. Patients with metastatic status need new treatment strategies. Search for new predictive markers is required for early detection of resistant to conventional treatment patients with localized pPNET.
P = 0.0016). Fifteen-year OS for the entire cohort of patients was 60.2 %. Known clinical prognostic factors (age, sex, tumors volume, response to treatment and other) did not differ between patients with favorable and unfavorable outcomes.
Treatment results for pediatric patients with pPNET from the Republic of Belarus comply with the generally accepted standards. Patients with metastatic status need new treatment strategies. Search for new predictive markers is required for early detection of resistant to conventional treatment patients with localized pPNET.
About the Authors
L. Kisialeu
Republican Research Center for Pediatric Oncology, Hematology and Immunology
Belarus
Ph. D. (Med.), Chief of the Department.
Belarus
Ph. D. (Med.), Chief of the Department.
O. Aleinikova
Republican Research Center for Pediatric Oncology, Hematology and Immunology
Belarus
Corresponding Member, D. Sc. (Med.), Professor, Director
Belarus
Corresponding Member, D. Sc. (Med.), Professor, Director
References
1. Достижения детской онкологии и гематологии в Республике Беларусь // О. В. Алейникова [и др.] // Актуальные вопросы детской онкологии и гематологии: материалы VIII междунар. симп. – Минск, 2000. – C. 3–8.
2. Суконко, О. Г. Организационно-методическая помощь, оказываемая государственным учреждением РНПЦ ОМР им. Н. Н. Александрова организациям здравоохранения в Республике Беларусь / О. Г. Суконко, Н. А. Антоненкова // Онкол. журн. – 2011. – № 20. – С. 42–45.
3. Неоперируемый рак щитовидной железы: эффективность диагностики и выживаемость / Ю. Е. Демидчик [и др.] // Онкол. журн. – 2008. – № 8. – С. 9–21.
4. Роль молекулярных часов в патогенезе и терапии злокачественных новообразований / Э. А. Жаврид [и др.] // Мед. панорама. – 2011. – № 7. – С. 19–23.
5. Declining childhood and adolescent cancer mortality / M. A. Smith [et al.] // Cancer. – 2014. – N 120. – P. 2497–2506.
6. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma / M. A. Applebaum [et al.] // Cancer. – 2011. – Vol. 117 (13). – P. 3027–3032.
7. Up-to-date monitoring of childhood cancer long-term survival in Europe: tumours of the sympathetic nervous system, retinoblastoma, renal and bone tumours, and soft tissue sarcomas / V. Arndt [et al.] // Ann. Oncol. – 2007. – N 18. – P. 1722–1733.
8. Ewing’s sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991 / R. B. Raney [et al.] // J. Clin. Oncol. – 1997. – Vol. 15 (2). – P. 574–582.
9. Петрович, С. Эпидемиологические аспекты детской онкогематологической заболеваемости в Республике Беларусь / С. Петрович, O. Алейникова, T. Ш�умихина // Вопр. онкол. – 2002. – Т. 48 (3). – С. 301–305.
10. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V / R. B. Raney [et al.] //J. Pediatr. Hematol. Oncol. – N 23. – P. 215–220.
11. Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients / M. Paulussen [et al.] // J. Clin. Oncol. – 2008. – N 26. – P. 4385–4393.
12. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumours: a Children’s Oncology Group Study / L. Granowetter [et al.] // J. Clin. Oncol. – 2009. – N 27. – P. 2536–2541.
13. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumours: a study by the Societe Francaise des Cancers de l’Enfant / O. Oberlin [et al.] // J. Clin. Oncol. – 2006. – N 24. – P. 3997–4002.
14. �Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin and etoposide (VIDE) in the treat-treatment of Ewing tumours in the EURO-E.W.I.N.G. 99 clinical trial / C. Juergens [et al.] // Pediatr. Blood Cancer. – 2006. – N 47. – P. 22–29.
15. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health Workshop / V. G. de Gruttola [et al.] // Control. Clin. Trials. – 2001. – N 2. – P. 485–502.
16. Raney R. B., Anderson J. R., Barr F. G., Donaldson S. S., Pappo A. S., Qualman S. J., Wiener E. S., Maurer H. M., Crist W. M. “Rhabdomyosarcoma, undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience, rationale for Intergroup Rhabdomyosarcoma Study V”, Journal of Pediatric Hematology/Oncology, 2001, no. 23, pp. 215–220.
17. Paulussen M., Craft A. W., Lewis I., Hackshaw A., Douglas C., Dunst J., Schuck A., Winkelmann W., Köhler G., Poremba C., Zoubek A., Ladenstein R., van den Berg H., Hunold A., Cassoni A., Spooner D., Grimer R., Whelan J., McTiernan A., Jürgens H. “Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients, assessment of benefit of etoposide added to standard treatment in high-risk patients”, Journal of Clinical Oncology, 2008, no. 26, pp. 4385–4393.
18. Granowetter L., Womer R., Devidas M., Krailo M., Wang C., Bernstein M., Marina N., Leavey P., Gebhardt M., Healey J., Shamberger R. C., Goorin A., Miser J., Meyer J., Arndt C. A., Sailer S., Marcus K., Perlman E., Dickman P., Grier H. E. “Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumours: a Children’s Oncology Group Study”, Journal of Clinical Oncology, 2009, no. 27, pp. 2536–2541.
19. Oberlin O., Rey A., Desfachelles A. S., Philip T., Plantaz D., Schmitt C., Plouvier E., Lejars O., Rubie H., Terrier P., Michon J. “Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumours: a study by the Societe Francaise des Cancers de l’Enfant”, Journal of Clinical Oncology, 2006, no. 24, pp. 3997–4002.
20. Juergens C., Weston C., Lewis I., Whelan J., Paulussen M., Oberlin O., Michon J., Zoubek A., Juergens H., Craft A. “Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, etoposide (VIDE) in the treatment of Ewing tumours in the EURO-E.W.I.N.G. 99 clinical trial”, Pediatric Blood, Cancer, 2006, no. 47, рр. 22–29.
21. De Gruttola V. G., Clax P., Demets D. L., Downing G. J., Ellenberg S. S., Friedman L., Gail M. H., Prentice R., Wittes J., Zeger S. L. “Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health Workshop”, Controlled Clinical Trials, 2001, no. 22, рр. 485–502.
Review
For citations:
Kisialeu L., Aleinikova O. CLINICAL OUTCOMES AND SURVIVAL RATES OVER THE 15-YEAR PERIOD IN PEDIATRIC PATIENTS WITH PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR OF BONE AND SOFT TISSUES IN REPUBLIC OF BELARUS. Proceedings of the National Academy of Sciences of Belarus, Medical series. 2017;(1):38-45. (In Russ.)
Views: 590
Email this article 